Tesamorelin
Stabilized GHRH analog studied for visceral fat reduction
Half-life
~26 min
Typical Dose
1-2mg daily
Format
Injectable
Purity
≥98%
Overview
Tesamorelin is a stabilized GHRH analog clinically studied for reducing visceral adipose tissue. FDA-approved for HIV-associated lipodystrophy and researched for its body composition effects.
Mechanism
Stabilized GHRH(1-44) with extended half-life. Stimulates pulsatile GH release, increases IGF-1, and preferentially reduces visceral adipose tissue.
Researched benefits
- Visceral fat reduction
- Improved lipid profiles
- Cognitive benefits in studies
- Once-daily dosing
Frequently asked
What is tesamorelin approved for?
Tesamorelin is FDA-approved as Egrifta for reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That is the only approved indication; other uses are investigational.
Why does tesamorelin target visceral fat specifically?
Visceral adipose tissue is more lipolytically responsive to growth hormone than subcutaneous fat, with higher GH receptor density and greater catecholamine sensitivity. Raising pulsatile GH therefore reduces the visceral depot preferentially.
Tesamorelin vs sermorelin?
Tesamorelin is a stabilized GHRH(1-44) analog with a trans-3-hexenoyl modification that resists DPP-4 degradation, giving it a longer half-life. Sermorelin is the unmodified GHRH(1-29) fragment and clears within minutes.
How is tesamorelin dosed?
Clinical protocols use once-daily subcutaneous injection. Unlike shorter GHRH fragments that are timed to sleep pulses, tesamorelin's stability allows a fixed daily schedule.
Ready to start your research
Get Tesamorelin from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy Tesamorelin now